본문 바로가기
KERD
논문KCI 등재

중등증-중증 지속성 알레르기비염 환아에서 경구용 2세대 항히스타민제(Zyrtec )와 류코트리엔 수용체 길항제(Singulair )의 치료효과

The Efficacy of Leukotriene Receptor Antagonist and Second generation Anti-histamine in Treatment for Children with Moderate to Severe Persistent Allergic Rhinitis (PAR)

김지은|정진아|이영석|이주석|강태곤|안혜성
대한 소아알레르기 호흡기학회 (The Korean Academy Of Pediatric Allergy And Respiratory Disease)|2008.06|Allergy Asthma & Respiratory Disease (알레르기 천식 호흡기질환)|제18권 제2호|pp. 49-57

0

조회

0

다운로드

1

인용

0

참고문헌

키워드

Allergic rhinitisLeukotriene receptor antagonistSecond generation anti-histamine
주제분류소아과학

초록

Purpose:We evaluated the efficacy of leukotriene receptor antagonist and second generation anti-histamine in children with moderate to severe persistent allergic rhinitis. Methods:Twenty eight patients who were treated with second generation anti-histamine for 4 weeks (Zyrtec syrupⓇ, Group A)and 58 patients who were treated with leukotriene receptor antagonist for 4 weeks (SingulairⓇ, Group B) were enrolled in this study. Control group (n=22) was received only first generation anti-histamine (Hydroxyzine) intermittently. Efficacy were evaluated by nasal scores in nasal congestion, rhinorrhea, nasal itching, sneezing and total nasal symptom score (a sum of patient ratings of nasal congestion, rhinorrhea, nasal itching, sneezing) before treatment and at 2 and 4 weeks after treatment. Results:There were no difference in the total IgE and total eosinophil count of 3 groups. There were also no significant difference in the initial symptom scores. For nasal congestion, group A and B showed significant improvement at 2 and 4 weeks after treatment compared with controls (each P=0.006, P=0.000, P=0.023, P=0.001). For sneezing, group A and B showed significant improvement at 2 weeks after treatment compared with controls (each P=0.048, P=0.011) and group B also showed significant improvement at 4 weeks after treatment compared with controls (P=0.041). In total nasal symptom score (TNSS), group A and B showed significant improvement at 2 and 4 weeks after treatment compared with controls (each P=0.014, P=0.005, P=0.008, P=0.005). Conclusion:In the moderate to severe persistent allergic rhinitis, leukotriene receptor antagonist or second generation anti-histamine is effective in nasal congestion and sneezing.

Abstract

Purpose:We evaluated the efficacy of leukotriene receptor antagonist and second generation anti-histamine in children with moderate to severe persistent allergic rhinitis. Methods:Twenty eight patients who were treated with second generation anti-histamine for 4 weeks (Zyrtec syrupⓇ, Group A)and 58 patients who were treated with leukotriene receptor antagonist for 4 weeks (SingulairⓇ, Group B) were enrolled in this study. Control group (n=22) was received only first generation anti-histamine (Hydroxyzine) intermittently. Efficacy were evaluated by nasal scores in nasal congestion, rhinorrhea, nasal itching, sneezing and total nasal symptom score (a sum of patient ratings of nasal congestion, rhinorrhea, nasal itching, sneezing) before treatment and at 2 and 4 weeks after treatment. Results:There were no difference in the total IgE and total eosinophil count of 3 groups. There were also no significant difference in the initial symptom scores. For nasal congestion, group A and B showed significant improvement at 2 and 4 weeks after treatment compared with controls (each P=0.006, P=0.000, P=0.023, P=0.001). For sneezing, group A and B showed significant improvement at 2 weeks after treatment compared with controls (each P=0.048, P=0.011) and group B also showed significant improvement at 4 weeks after treatment compared with controls (P=0.041). In total nasal symptom score (TNSS), group A and B showed significant improvement at 2 and 4 weeks after treatment compared with controls (each P=0.014, P=0.005, P=0.008, P=0.005). Conclusion:In the moderate to severe persistent allergic rhinitis, leukotriene receptor antagonist or second generation anti-histamine is effective in nasal congestion and sneezing.

참고문헌 (32)

  1. Baraniuk JN, "Pathogenesis of allergic rhinitis", J Allergy Clin Immunol, 99, pp.S763~S772 (1997)
  2. Miadonna A, "Behavior and clinical relevance of histamine and leukotrienes C4 and B4 in grass pollen-induced rhinitis", Am Rev Respir Dis, 136, pp.357~362 (1987)
  3. Creticos PS, "Peptide leukotriene release after antigen challenge in patients sensitive to ragweed", N Engl J Med, 310, pp.1626~1630 (1984)
  4. Busse W, "The role of leukotrienes in asthma and allergic rhinitis", Clin Exp Allergy, 26, pp.868~879 (1996)
  5. Bisgaard H, "Effect of leukotriene D4 on nasal mucosal blood flow, nasal airway resistance and nasal secretion in humans", Clin Allergy, 16, pp.289~297 (1986)
  6. Okayama Y, "In vitro effects of H1-antihistamines on histamine and PGD2 release from mast cells of human lung, tonsil, and skin", Allergy, 49, pp.246~253 (1994)
  7. Michel L, "Inhibitory effect of oral cetirizine on in vivo antigen-induced histamine and PAF-acether release and eosinophil recruitment in human skin", J Allergy Clin Immunol, 82, pp.101~109 (1988)
  8. Charlesworth EN, "Effect of H1 receptor blockade on the early and late response to cutaneous allergen challenge", J Pharmacol Exp Ther, 262, pp.964~970 (1992)
  9. Rédier H, "Inhibitory effect of cetirizine on the bronchial eosinophil recruitment induced by allergen inhalation challenge in allergic patients with asthma", J Allergy Clin Immunol, 90, pp.215~224 (1992)
  10. Bousquet J, "Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaborates with the World Health Organization, GA(2)LEN and AllerGen)", Allergy, 63(86), pp.8~160 (2008)
  11. Nimmagadda SR, "Allergy: etiology and epidemiology", Pediatr Rev, 20, pp.111~115 (1999)
  12. Johansson SG, "Revised nomenclature for allergy for globar use : Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003", J Allergy Clin Immunol, 113, pp.832~836 (2004)
  13. Saito H, "Effects of a cysteinyl leukotriene receptor antagonist on eosinophil recruitment in experimental allergic rhinitis", Immunology, 113, pp.246~252 (2004)
  14. van Cauwenberge P, "Consensus statement on the treatment of allergic rhinitis", Allergy, 55, pp.116~134 (2000)
  15. Mansmann HC Jr, "Efficacy and safety of cetirizine therapy in perennial allergic rhinitis", Ann Allergy, 68, pp.348~353 (1992)
  16. Howarth PH, "Double-blind, placebo-controlled study comparing the efficacy and safety of fexofenadine hydrochloride (120 and 180 mg once daily) and cetirizine in seasonal allergic rhinitis", J Allergy Clin Immunol, 104, pp.927~933 (1999)
  17. Lockey RF, "Comparative study of cetirizine and terfenadine versus placebo in the symptomatic management of seasonal allergic rhinitis", Ann Allergy Asthma Immunol, 76, pp.448~454 (1996)
  18. Hsieh JC, "A comparison of cetirizine and montelukast for treating childhood perennial allergic rhinitis", Pediatr Asthma Allergy Jmmunol, 17, pp.59~69 (2004)
  19. Lipworth BJ, "Differences in in vitro H1-receptor antagonist potency with fexofenadine and desloratadine do not determine effects on nasal congestion in seasonal allergic rhinitis", Allergy, 57(73), pp.10~ (2002)
  20. Horak F, "Effect of desloratadine versus placebo on nasal airflow and subjective measures of nasal obstruction in subjects with grass pollen- induced allergic rhinitis in an allergen-exposure unit", J Allergy Clin Immuol, 109, pp.956~961 (2002)
  21. Ciprandi G, "Fexofenadine treatment reduces nasal congestion in allergic rhinitis", Allergy, 56, pp.1068~1070 (2001)
  22. Ciprandi G, "Levocetirizine improves nasal obstruction and moudulates cytokine pattern in patients with seasonal allergic rhinitis: a pilot study", Clin Exp Allergy, 34, pp.958~964 (2004)
  23. Christodoulopoulos P, "Molecular pathology of allergic disease. II: Upper airway disease", J Allergy Clin Immunol, 105, pp.211~223 (2000)
  24. Bachert C, "Regulation of proinflammatory cytokines in seasonal allergic rhinitis", Int Arch Allergy Immunol, 118, pp.375~379 (1999)
  25. KleinJan A, "Increase in IL-8, IL-10, IL-13, and RANTES mRNA levels (in situ hybridization) in the nasal mucosa after nasal allergen provocation", J Allergy Clin Immunol, 103, pp.441~450 (1999)
  26. Jin HR, "Cetirizine decreases IL-4, IL-5 and IFN gamma gene expressions in nasal-associated lymphoid tissue of sensitized mice", Am J Rhinol, 16, pp.43~48 (2002)
  27. Arnold R, "Cetirizine counter-regulates IL-8 release from human epithelial cells(A549)", Clin Exp Allergy, 29, pp.1681~1691 (1999)
  28. Howarth PH, "Leukotrienes in rhinitis", Am J Respir Crit Care Med, 161, pp.S133~S136 (2000)
  29. Nathan RA, "Pharmacotherapy for allergic rhinitis: a critical review of leukotriene receptor antagonists compared with other treatments", Ann Allergy Asthma Immunol, 90, pp.182~190 (2003)
  30. Philip G, "Montelukast for treating seasonal allergic rhinitis: a randomized, double-blind, placebo-controlled trial performed in the spring", Clin Exp Allergy, 32, pp.1020~1028 (2002)
  31. Nayak AS, "Efficacy and tolerability of montelukast alone or in combination with loratadine in seasonal allergic rhinitis: a multicenter, randomized, double-blind, placebo-controlled trial performed in the fall", Ann Allergy Athma Immunol, 88, pp.592~600 (2002)
  32. Ho CY, "Comparison of antileukotrienes and antihistamines in the treatment of allergic rhinitis", Am J Rhinol, 21, pp.439~443 (2007)

이 간행물의 다른 논문 (10건)

소아 천식의 예후와 폐기능염혜영pp. 1-3Siglec-8: 천식의 호산구성 염증과기도개형에 대한 새로운 치료적 접근송대진pp. 4-11소아 IgA 결핍증의 임상양상과 면역학적 특징고용민, 김유진, 이윤희, 이현승, 김진택, 이근영, 이준성, 윤종서, 이혜경, 김현희pp. 12-19선천성 낭성 선종양 폐기형의 임상적 고찰전소은, 박희주pp. 20-28학동기 천식에서 성인 초기까지 천식의 지속에 미치는인자들 : 폐기능 및 기관지 과민성을 중심으로강임주, 김재진, 박종진pp. 29-38
원문 보기